Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.52 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.52 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.52 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.52 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.52 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.52 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.52 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.51 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.51 |
| ▸ | CASR known ✓ | P41180 | 1/20 | 0.36 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.36 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MPI | P34949 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900644 | 0.99 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| Hydrochloric Acid SCHEMBL3422321 | 0.89 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL7886328 | 0.88 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL900661 | 0.88 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL2899691 | 0.86 | MAPT (0.55) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| Hydrochloric Acid SCHEMBL11357932 | 0.86 | KDM4E (0.54) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| Bromide SCHEMBL7147879 | 0.85 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL5108689 | 0.85 | KDM4E (0.51) | ADRA2AADRA2BADRA2CADRA1AKDM4E | |
| SCHEMBL2902371 | 0.85 | KDM4E (0.51) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL28430176 | 0.83 | ENPP2 (0.43) | ADRA2AADRA2BADRA2CADRA1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475663-A2 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | Actavis Group Ptc Ehf (IS) | 2012-07-18 | — | — | EP | claimed |
| US-20120164188-A1 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | ACTAVIS GROUP PTC EHF (IS) | 2012-06-28 | — | — | US | claimed |
| WO-2012042368-A1 | PROCESS FOR PREPARATION OF PALIPERIDONE | AUROBINDO PHARMA LIMITED (IN) | 2012-04-05 | — | — | WO | claimed |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | US | claimed |
| WO-2011073997-A2 | PROCESS FOR PREPARING PALIPERIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-06-23 | — | — | WO | claimed |
| EP-2300467-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN Laboratories Limited (IN) | 2011-03-30 | — | — | EP | claimed |
| WO-2011030224-A2 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | ACTAVIS GROUP PTC EHF (IS) | 2011-03-17 | — | — | WO | claimed |
| WO-2010004578-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN LABORATORIES LIMITED (IN) | 2010-01-14 | — | — | WO | claimed |
| CN-114616229-B | Tricyclic compounds and pharmaceutical uses thereof | 镇斗生物科技股份公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD BIOSCIENCE INC. (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-4053116-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD Bioscience Inc. (KR) | 2022-09-07 | — | — | EP | disclosed |
| EP-2303877-B1 | PROCESS TO PREPARE PALIPERIDONE AND INTERMEDIATES THEREOF | INKE SA (ES) | 2017-02-15 | — | — | EP | disclosed |
| US-8481729-B2 | Processes for the preparation of paliperidone | MSN LABORATORIES LIMITED (IN) | 2013-07-09 | — | — | US | disclosed |
| US-8309717-B2 | Process to prepare paliperidone and intermediates thereof | INKE, S.A. (ES) | 2012-11-13 | — | — | US | disclosed |
| EP-2300467-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN Laboratories Limited (IN) | 2011-03-30 | — | — | EP | disclosed |
| WO-2011030224-A2 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | ACTAVIS GROUP PTC EHF (IS) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010064134-A2 | PROCESS OF SYNTHESIS OF PALIPERIDONE | CADILA PHARMACEUTICALS LTD. (IN) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010004578-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN LABORATORIES LIMITED (IN) | 2010-01-14 | — | — | WO | disclosed |
| US-20100004447-A1 | PROCESS FOR PREPARATION OF 9-HYDROXY-3-(2-CHLOROETHYL)-2-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE HYDROCHLORIDE | ACTAVIS GROUP PTC EHF (IS) | 2010-01-07 | — | — | US | disclosed |
| WO-2009144288-A1 | PROCESS TO PREPARE PALIPERIDONE AND INTERMEDIATES THEREOF | INKE, S.A. (ES) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TPH1, SLC6A4, TPH2 | ADRA2A 419/4885ADRA2B 316/4885ADRA2C 100/4885 |
| US-20100004447-A1 | PROCESS FOR PREPARATION OF 9-HYDROXY-3-(2-CHLOROETHYL)-2-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE HYDROCHLORIDE | PAH, DPYD, TPMT | ADRA2A 340/4885ADRA2B 548/4885ADRA2C 435/4885 |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | AVPR2, AVPR1B, AVPR1A | ADRA2A 503/4885ADRA2B 408/4885ADRA2C 870/4885 |
| US-20120164188-A1 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | REN, DHPS, AVPR2 | ADRA2A 359/4885ADRA2B 600/4885ADRA2C 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.